PyramIDH

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
48 patients (estimated)
Sponsors
Institut de Recherches Internationales Servier
Collaborators
Servier Bio-Innovation LLC
Tags
Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, Randomization
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2062
NCT Identifier
NCT06465953

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.